Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib versus single-agent chemotherapy in germline BRCA-mutated platinum-sensitive relapsed ovarian cancer
MOH_2017-03-01_000173Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olaparib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by AstraZeneca. Started Mar 2015; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2017-03-01_000173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-01_000173.